Neuphoria Therapeutics Inc. (NEUP)
NASDAQ: NEUP · Real-Time Price · USD
4.570
+0.220 (5.06%)
At close: Jun 26, 2026, 4:00 PM EDT
4.550
-0.020 (-0.44%)
Pre-market: Jun 29, 2026, 6:43 AM EDT

Neuphoria Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
2514101853-
Market Cap Growth
83.75%38.31%-43.43%-65.84%--
Enterprise Value
5.29-0.05-2.216.229.890
Last Close Price
4.577.109.2026.4083.88-
PS Ratio
-1861.670.90----
PB Ratio
0.840.740.580.821.34-
P/TBV Ratio
0.992.072.302.501.73-
P/FCF Ratio
-181.89----
P/OCF Ratio
-181.89----
EV/Sales Ratio
-0.00----
EV/EBITDA Ratio
-0.100.13-2.53-
EV/EBIT Ratio
-0.040.12-2.71-
EV/FCF Ratio
--0.15---
Debt / Equity Ratio
-00.010.010.010.01
Debt / EBITDA Ratio
----0.040.12
Debt / FCF Ratio
-1.51----
Net Debt / Equity Ratio
-0.66-0.74-0.71-0.53-0.58-0.58
Net Debt / EBITDA Ratio
1.2130.230.720.55-1.92-3.70
Net Debt / FCF Ratio
1.13-182.500.840.831.513.67
Asset Turnover
0.000.560000
Quick Ratio
13.913.373.334.5710.0012.07
Current Ratio
14.313.563.454.8712.4613.10
Return on Equity (ROE)
-58.96%-2.03%-78.44%-69.80%-40.05%-29.35%
Return on Assets (ROA)
-45.96%-1.77%-63.30%-59.34%25.52%13.12%
Return on Invested Capital (ROIC)
-121.26%-3.53%-118.90%-117.28%53.08%19.65%
Return on Capital Employed (ROCE)
-49.80%-4.69%-72.08%-64.13%27.03%15.16%
FCF Yield
-0.55%----
Buyback Yield / Dilution
-161.08%-95.01%-22.38%-8.53%-73.52%99.93%
Total Shareholder Return
-161.08%-95.01%-22.38%-8.53%-73.52%99.93%
SEC Filings: 10-K · 10-Q